DR-445 Predicting and evaluating resistance to CDK4/6 therapies in metastatic Breast Cancer Patients

This project aims to predict the response of luminal metastatic breast cancer patients to standard of care treatment, helping to optimize therapy selection. Using transcriptome sequencing of preserved tumour biopsies from 90 patients in the SOLTI-1801 CDK-PREDICT study, we identified key gene expression patterns associated with treatment response. Through differential expression analysis and Cox regression models, we defined three transcriptional signatures, which demonstrated high predictive accuracy in an independent cohort. These findings could improve personalized treatment decisions, ensuring patients receive the most effective therapies while avoiding unnecessary side effects. Further validation in an external cohort will confirm clinical applicability.

Marcos Malumbres Martínez, Vall d’Hebron Institute of Oncology (VHIO), Spain